Lacidofil
ApprovedSmall molecule
Lacidofil is one of 45 small molecule programs targeting Gastroenteritis. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Lacidofil
NNational Health Insurance Service Ilsan Hospital
Approved
Primaquine
SanofiPreclinical
Jakafi
IncytePreclinical
Innohep
Alnylam PharmaceuticalsPreclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Advil
KKenvue Brands
Preclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Tagamet
DDT MedTech, LLC
Preclinical
Prilosec
DDexcel Pharma Technologies Ltd.
Preclinical
Prograf
VVeloxis Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pneumonia1 trial
Impact of Probiotics on Antibiotic-associated Diarrhea in Community-acquired Pneumonia
Not yet recruiting·NNational Health Insurance Service Ilsan Hospital·Phase 4·NCT06990568·100 enrolled
Gastroenteritis1 trial
Emergency Department Probiotic Treatment of Pediatric Gastroenteritis
Completed·—·Phase 3·NCT01853124·886 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lacidofil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details